EGCG
(2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate)

Faint pink solid. PROTECT FROM LIGHT. PACKAGED UNDER INERT GAS. One of the main polyphenolic constituents of green tea that exhibits potent antitumor, anti-inflammatory, and antioxidant properties. Arrests cell cycling at G₀/G₁ phase and induces apoptosis in a dose-dependent manner. Shown to inhibit PMA-induced skin thickening and to activate of protein kinase C. Also activates ornithine decarboxylase and interleukin-1a mRNA and protein expression. Acts as an inhibitor of inducible nitric oxide synthase (iNOS) gene expression and enzyme activity. Also blocks peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine. Strongly and directly inhibits telomerase in cell-free systems and in cancer cell lines. An inhibitor of Dnmt1 (IC₅₀ = 210-470nM). Purity: ≥98% by HPLC. RTECS KB5200000, CAS 989-51-5.

Merck Index: 14, 3526
Ref.: Dell'Aicia, I., et al. 2004. EMBO reports 5, 1. Tachibana, H., et al. 2004. Nat. Struct. Mol. Biol. 11, 380. Naasami, I., et al. 1998. Biochem. Biophys. Res. Commun. 249, 391. Ahmad, N., et al. 1997. J. Natl. Cancer 89, 1881. Chan, M.M.-Y., et al. 1997. Biochem. Pharmacol. 54, 1281. Lin, Y.-L., and Lin, J.-K. 1997. Mol. Pharmacol. 52, 465. Fiala, E.S., et al. 1996. Experientia 52, 922. Katiyar, S.K., et al. 1995. J. Invest. Dermatol. 105, 394. Liao, S., et al. 1995. Cancer Lett. 96, 239. Yamane, T., et al. 1995. Cancer Res. 55, 2081. Huang, M.T., et al. 1992. Carcinogenesis 13, 947.
R: 36/37/38; S: 26-36